Articles

Articles
Rengalin
Rengalin® is a treatment for non-productive and productive cough in adults and children from 3 years of age.
5 Articles and research data
Ergoferon
Ergoferon® has an enhanced potency owing to the combination of antiviral, anti-inflammatory and antihistamine effects.
4 Articles and research data
Tenoten for children
Tenoten for children® is the only anti-anxiety drug designed specifically for pediatric patients taking in account the peculiarities of children's mental health.
6 Articles and research data
Tenoten
Tenoten® is an anti-anxiety drug with stress protective activity.
18 Articles and research data

Tenoten

Tenoten® is an anti-anxiety drug with stress protective activity.
Information about the preparation

Clinic

Bull Exp Biol Med. 2009 Aug;148(2):343-5. Tenoten in the therapy of anxious disturbances in patients with essential hypertension and coronary heart disease. Vanchakova NP, Popov AP.
Bull Exp Biol Med. 2009 Aug;148(2):351-2. Efficiency of antianxiety preparation tenoten used in complex therapy of patients with Helycobacter pylory-associated ulcer disease of the duodenum. Tsukanov VV, Kupershtein EY, Sharypova VN.
Bull Exp Biol Med. 2009 Aug;148(2):346-8. Clinical effects of anxiolytic preparation tenoten in complex therapy of essential hypertension. Nikol'skaya IN, Guseva IA, Bliznevskaya EV, Tret'yakova TV.
Bull Exp Biol Med. 2009 Aug;148(2):340-2. The use of tenoten and tenoten (pediatric formulation) as a drug for premedication in adults and children during outpatients dentist visit. Larentsova LI, Lyubimova DV, Fokina TY, Rvacheva EA, Sosul'nikov DV.
Psychosocial target for cognitive-saving therapy in the modern patient
Reshetova T.V., Reshetov A.V.

Preclinical

Antibodies to calcium-binding S100B protein block the conditioning of long-term sensitization in the terrestrial snail
Vyatcheslav V.Andrianov, Oleg I.Epstein, Tatiana Kh. Gainutdinova, Mark B. Shtark, Aliya Kh. Timoshenko, Khalil L. Gainutdinov
Protective Effect of Low-Doses of Antibodies to S-100 Protein on the Formation of Long-Term Sensitization in Helix Lucorum
O. I. Epstein, M. B. Stark, A. Kh. Timoshenko, T. Kh. Gainutdinova, and Kh. L. Gainutdinov
Neurotropic Compounds and Their Antibodies: Effect on the Brain System of Positive Emotional Reinforcement
O.I. Epstein, T.M. Vorob´eva, V.V. Geiko, I.R.Pan, and  O.G. Berchenko
Membranotropic Effects of Antibodies to S100 Protein in Ulrtalow Doses
V.V. Andrianov, Kh.L. Gainutdion, T.Kh. Gainutdinova, D.I. Mukhamedshina, M.B. Shtark, and O.I. Epstein
Antibodies to S100 proteins have anxiolytic-like activity at ultra-low doses in the adult rat
Vincent Castagne, Martine Lemaire, Irina Kheyfets, Julia L. Dugina, Svetlana A. Sergeeva and Oleg I. Epstein
Membrane and Synaptic Effects of Anti-S-100 are Prevented by the Same Antibodies in Low Concentrations
O.I. Epstein, N.A. Beregovoy, N.S. Sorokina, M.Y. Starostina, M.B. Shtark, Kh.L. Gainutdinov, T.Kh. Gainutdinova, D.I. Muhamedshina
Plasticity of Neuronal Responses Induced by Low Concentrations of Exogenous Ligands Affecting Cellular Calcium Stores
Epstein O.I., Zapara T.A., Simonova O.G., Ratushnyak A.S., Shtark M.B.
A Comparison of the Dynamics of S100B, S100A1, and S100A6 mRNA Expression in Hippocampal CA1 Area of Rats during Long-TermPotentiation and after Low-Frequency Stimulation
Pavel D. Lisachev,  Mark B. Shtark, Olga O. Sokolova, Vladimir O. Pustylnyak, Mary Yu. Salakhutdinova, and Oleg I. Epstein
Anxiolytic Activity of Tenoten and Diazepam Depends on Conditions in Vogel Confl ict Test
I. A. Kheyfets, T. A. Voronina, J. L. Dugina, G. M. Molodavkin, and S. A. Sergeeva
Antiaggressive Activity of Antibodies to S-100 Protein in Ultralow Doses
T. A. Voronina, I. A. Kheyfets, G. M. Molodavkin, Yu. L. Dugina, M. V. Borodavkina, S. A. Sergeeva, and O. I. Epshtein
Involvement of the GABA-B System in the Mechanism of Action of Ultralow-Dose Antibodies to S-100 Protein
I. A. Kheifez, G. M. Molodavkin, T. A. Voronina, Yu. L. Dugina, S. A. Sergeeva, and O. I. Epstein
Psychotropic Drug Tenoten Activates Mitogen-Activated MAP/ERK Kinase Regulatory Cascade Controlling the Neuroprotective Effects
O. I. Epstein, O. V. Vorobieva, L. N. Grinkevich, O. A. Kharchenko, and M. B. Shtark
In vitro screening of major neurotransmitter systems possibly involved in the mechanism of action of antibodies to S100 protein in released-active form
Evgeniy A Gorbunov, Irina A Ertuzun, Evgeniya V Kachaeva, Sergey A Tarasov, Oleg I Epstein
Divaza
Divaza®: a modern-day nootropic and vasoactive drug with a novel mechanism of action intended to treat chronic cerebrovascular disorders.
6 Articles and research data
Brizantin
Brizantin® is a nicotine-free drug with a complex mechanism of action aimed at alleviating symptoms of smoking withdrawal and reducing smoking addition.
1 Articles and research data
Arthrofoon
Arthrofoon® is specially designed as a long-term therapy for chronic inflammatory joint diseases, and as an aid in recovery after joint disease exacerbations.
11 Articles and research data

Arthrofoon

Arthrofoon® is specially designed as a long-term therapy for chronic inflammatory joint diseases, and as an aid in recovery after joint disease exacerbations.
Information about the preparation

Clinic

Treatment of early arthritis using arthrofoon (ultra-low doses of antibodies to tumor necrosis factor-α)
Laudmila V.Sizova
Effi ciency and Safety of Long-Term Artrofoon Treatment in Rheumatoid Arthritis
V. I. Petrov, A. R. Babaeva, E. V. Cherevkova, M. V. Kachanova, Yu. A. Zabolotneva, S. A. Tarasov, Yu. L. Dugina, and S. A. Sergeeva
Bull Exp Biol Med. 2009 Sep;148(3):489-92. Effect of combination of anticytokine preparations anaferon and artrofoon on immune inflammation in rheumatoid arthritis. Petrov VI, Babaeva AR, Solodenkova KS, Cherevkova EV, Zabolotneva YA, Kachanova MV, Sergeeva SA.
Adv Gerontol. 2010;23(3):453-8. Influence of Artrofoon on the current of the metabolic syndrome in patients with rheumatoid arthritis. Vasil'eva LV, Lakhin DI.
Bull Exp Biol Med. 2009 Sep;148(3):478-81. The use of artrofoon in the therapy of disorders of the paraarticular apparatus. Khitrov NA.
Bull Exp Biol Med. 2009 Sep;148(3):474-7. The use of artrofoon in the treatment of ankylosing spondyloarthritis. Kudryavtseva IV, Ukolova LA, Chizhov NN, Braginskaya NM, Istranen IA, Kozhevnikov OP.
Bull Exp Biol Med. 2009 Sep;148(3):470-3. Efficiency and tolerability of artrofoon (ultralow doses and antibodies to TNF-alpha) in osteoarthrosis. Alikhanov BA, Pavlenko AY.
Bull Exp Biol Med. 2009 Sep;148(3):468-9. Clinical efficiency and tolerability of artrofoon in patients with rheumatoid arthritis associated with osteopenic syndrome. Peshekhonova LK, Chernov YN, Barsukova NA, Peshekhonov DV.
Ter Arkh. 2009;81(10):52-6. Low back pain in young subjects: a new approach to therapy. Shostak NA, Pravdiuk NG, Koriakina IN.
Bull Exp Biol Med. 2008 Jan;145(1):58-61. Experimental and clinical study of the effect of artrofoon on proinflammatory cytokine production. Kachanova MV, Sherstoboyev EY, Babayeva AR, Tcherevkova EV, Dugina JL, Kislitsyna OS, Epstein OI, Sergeeva SA.

Preclinical

Experimental and Clinical Study of the Effect of Artrofoon on Proinflammatory Cytokine Production
M. V. Kachanova, E. Yu. Sherstoboyev, A. R. Babayeva, E. V. Tcherevkova, J. L. Dugina, O. S. Kislitsyna, O. I. Epstein, and S. A. Sergeeva
Afala
Afala® is a state-of the-art drug designed to treat benign prostatic hypertrophy and chronic prostatitis.
10 Articles and research data

Afala

Afala® is a state-of the-art drug designed to treat benign prostatic hypertrophy and chronic prostatitis.
Information about the preparation

Clinic

Clinical Study of the Effi ciency and Safety of Afala in Patients with Benign Prostatic Hyperplasia
K. V. Savel’eva, M. V. Kachanova, V. N. Pavlov, R. A. Kazikhinurov, M. Yu. Frolov, A. B. Mukhin, V. V. Udut, Z. A. Yurmazov,  Yu. L. Dugina, S. A. Sergeeva, and O. I. Epshtein
Treatment and the preventive maintenance of erectile dysfunction in patients with prostate gland disease  
S.Kalinina
A Novel  Antibody-based Therapeutic for Benign Prostate Hyperplasin: Result of a Randomized Clinical Trial    
 J.L.Dugina, K.V.Savelieva, S.A. Sergeev, O.I.Epstein
Urologiia. 2012 Sep-Oct;(6):52-4, 56-7. Afala in the treatment of patients with BPH: efficacy and safety. Grigor'ev MÉ.
Urologiia. 2009 May-Jun;(3):67-70. Administration of afala preparation in urological practice. Neĭmark AI, Isaenko VI, Iakovets IaV, Simashkevich AV, Aliev RT.
Bull Exp Biol Med. 2009 Aug;148(2):315-7. Efficiency of afala in complex therapy of patients with chronic prostatitis. Kul'chavenya EV.
Bull Exp Biol Med. 2009 Aug;148(2):312-4. Clinical use of afala in the therapy of chronic prostatitis. Tkachuk VN.
Bull Exp Biol Med. 2009 Aug;148(2):308-11. Experience of long-term afala treatment in benign prostatic hyperplasia. Gudkov AV.

Preclinical

Comparative Study of Pharmacological Activity of Afala on the Model of Hormone-Induced Prostatitis in Rats 
K. V. Savelieva, T. G. Borovskaya, I. A. Kheyfets, J. L. Dugina, S. A. Sergeeva, and O. I. Epstein
Effects of Ultralow Doses of Antibodies to Prostate-Specific Antigen on Morphological and Functional State of Rat Prostate  
 T.G.Borovskaya, T.I.Fomina, O.P. Loskutova, O.V. Baranova, S.A. Sergeeva, A.V. Martyushev,and O.I. Epstein
Impaza
An innovative drug used for the treatment of various forms of erectile dysfunction. For sale in Mexico.
13 Articles and research data

Impaza

An innovative drug used for the treatment of various forms of erectile dysfunction. For sale in Mexico.
Information about the preparation

Clinic

Impaza and Sildenafil: Comparison of Clinical Effectiveness in Patients with Erectile Dysfunction  
V.I.Petrov, A.S. Vekelyan, A.V.Martyushev, S.A.Sergeeva, I.V.Smolenov, and O.I. Epstein
Study of the Correlation between Clinical Efficiency of Impaza and Serum ADMA Level
E. S. Zhavbert, S. A. Tarasov, J. L. Dugina, S. A. Sergeeva, S. I. Gamidov, E. B. Mazo, and O. I. Epstein
Prophylactics of Erectile Dysfunction in Patients with Metabolic Syndrome
S. I. Gamidov, E. B. Mazo, R. V. Gasanov, and E. M. Sotnikova
Effi ciency of Combined Therapy with Impaza and Type 5 Phosphodiesterase Inhibitors in Prophylactics of Posttraumatic Erectile Dysfunction
Kh. S. Ibishev
Use of Impaza in the Treatment of Erectile Dysfunction in Patients with Essential Hypertension and CHD
A. I. Neimark, R. T. Aliev, N. I. Muzalevskaya, S. V. Krainichenko, E. N. Vorob’eva, and T. S. Tarasova
Evaluation of the Effi ciency and Safety of Combined Treatment with Impaza and Nitrates in CHD Patients with Erectile Dysfunction
E. S. Zhavbert, M. V. Kachanova, S. A. Tarasov, Yu. L. Dugina, S. A. Sergeeva, P. Ya. Dovgalevskii, and O. I. Epshtein
Georgian Med News. 2013 Jun;(219):61-5. The use of drugs Impaza and Nebido in the treatment of erectile dysfunction in patients with type 2 diabetes mellitus of reproductive age. Mehtiyev T.
Urologiia. 2013 Sep-Oct;(5):43-6, 48-9. Potentials for the correction of endothelial and erectile dysfunction in patients after coronary artery bypass grafting. Pomeshkin EV, Neĭmark AI, Pomeshkina SA, Barabash OL.

Preclinical

Sexual incentive motivation in old male rats: The effects of sildenafil and a compound (Impaza) stimulating endothelial NO synthase
Xi Chu a, Anders Ågmo
Sildenafil and a Compound Stimulating Endothelial NO Synthase Modify Sexual Incentive Motivation and Copulatory Behavior in Male Wistar and Fisher 344 Rats
Xi Chu, MSc, Ekaterina S. Zhavbert, MSc, Julia L. Dugina, MD, PhD, Irina A. Kheyfets, MSc, Svetlana A. Sergeeva, PhD, Oleg I. Epstein, MD, PhD, and Anders Ågmo, PhD
Sildenafil and a Compound Stimulating Endothelial NO Synthase Modify Sexual Incentive Motivation and Copulatory Behavior in Male Wistar and Fisher 344 Rats
Xi Chu, MSc, Ekaterina S. Zhavbert, MSc, Julia L. Dugina, MD, PhD, Irina A. Kheyfets, MSc, Svetlana A. Sergeeva, PhD, Oleg I. Epstein, MD, PhD, and Anders Ågmo, PhD
Experimental Study of the Effi ciency of Impaza on the Model of Chronic Aseptic Prostatic Infl ammation 
T. G. Borovskaya, T. I. Fomina, A. V. Pakhomova, L. A. Ermolaeva, M. E. Poluektova, E. S. Zhavbert, Ju. L. Dugina, I. A. Kheifets, and O. I. Epstein
Effects of Impaza on Sexual Behavior in Different Experimental Models
E. S. Zhavbert, J. L. Dugina, S. A. Sergeeva, I. A. Kheyfets, and O. I. Epstein
Anaferon
for Children
An innovative drug for the treatment and prevention of influenza. For sale in Cambodia.
18 Articles and research data

Anaferon for Children

An innovative drug for the treatment and prevention of influenza. For sale in Cambodia.
Information about the preparation

Clinic

The efficacy and safety of use of anaferon for children in the treatment of influenza and other acute respiratory viral infections in children
 E.Andrianova, M.Zak  Materia Medica Holding, Moscow, Russion
Evaluation of efficacy of interferon induser in prevention of the nosocomial gastrointestinal infections in children 
A.Gorelov Pediatric Clinical Departament, Central Research Institute of Epidemiology, Moscow, Russion
Oral antibody to interferon gamma in ultra low doses: clinical efficacy and interferon stimulation in patients with upper respiratory viral infections 
S.Tarasov, J.Dugina, S.Sergeeva, O.Epstein Materia Medica Holding, Moscow, Russion Federation
Application of Ultralow Doses of Antibodies to Interferon-γ in Complex Therapy of Bacterial Infections and Prophylaxis of Bacterial Complications
S. A. Tarasov, M. V. Kachanova, E. S. Zhavbert, Yu. L. Dugina, O. I. Epshtein, and S. A. Sergeeva
Infección de vías respiratorias agudas en población pediátrica
Bull Exp Biol Med. 2009 Aug;148(2):283-6. Acute viral infections with combined involvement of the respiratory and gastrointestinal tracts in children. Therapy with interferon. Dondurei EA, Osidak LV, Golovacheva EG, Golovanova AK, Amosova IV, Gladchenko LN.
Bull Exp Biol Med. 2009 Aug;148(2):275-8. Interferon status in children during acute respiratory infections. Therapy with interferon. Obraztsova EV, Osidak LV, Golovacheva EG, Afanas'eva OI, Mil'kint KK, Koroleva EG, Drinevskii VP, Vasil'eva IA.
Clinical Research and Trials. Anaferon, released-active from of antibodies to interferon-gamma, as an effective medicine for treatment and prophylaxis of a wide spectrum of infections Tarasov S.A., Kachanova M.V., Gorbunov E.A., Zabolotneva J.A., Ertuzun I.A., Belopolskaya M.V., Borodavkina M.V., Dugina J.L., Epstein OI.

Preclinical

Activity of ultra-low doses of antibodies to gamma-interferon against lethal influenza A(H1N1)2009 virus infection in mice 
Sergey A. Tarasov, Vladimir V. Zarubaev, Evgeniy A. Gorbunov, Svetlana A. Sergeeva, Oleg I. Epstein 
Novel Approach to Activity Evaluation for Release-Active Forms of Anti-Interferon-Gamma Antibodies Based on Enzyme-Linked Immunoassay 
Elena S. Gavrilova1, Sergey A. Bobrovnik, Gordon Sherriff, Andrey A. Myslivets, Sergey A. Tarasov, Oleg I. Epstein
Immunotropic Effects of Potentiated Antibodies to Human Interferon-γ
E.Yu.Sherstoboev, N.M.Mashaya, A.A.Churin, O.S.Borsuk, A.V.Martyushev, S.A.Sergeeva, O.I.Epstein, A.M. Dygai, and E.D.Goldberg
Study of Efficiency of Therapeutic and Preventive Anaferon (Pediatric Formulation) in Mice with Influenza Infection 
L. N. Shishkina, A. N. Sergeev, A. S. Kabanov, M. O. Skarnovich, N. K. Evtin, N. A. Mazurkova, A. A. Sergeev, M. V. Belopolskaya, I. A. Kheyfets, J. L. Dugina, S. A. Tarasov, S. A. Sergeeva, and O. I. Epstein
Antiviral Activity of Anaferon (Pediatric Formulation) in Mice Infected with Pandemic Infl uenza Virus A(H1N1/09) 
L. N. Shishkina, M. O. Skarnovich, A. S. Kabanov, A. A. Sergeev, S. E. Olkin, S. A. Tarasov, M. V. Belopolskaya, S. A. Sergeeva, O. I. Epstein, E. M. Malkova, E. A. Stavsky, and I. G. Drozdov
Antibodies to interferon-gamma in ultra-low doses: anew option for pandemic influenza 
S.Tarasov, V.Zarubaev, J.Tafani, J.Dugina, S.Sergeeva, O.Epstein (Moscow, St.Peterburg,RU; Maisons Alfrot, FR)
Antibiot Khimioter. 2013;58(5-6):17-23. Immunotropic properties of anaferon and anaferon pediatric. Zhavbert ES, Dugina IuL, Épshteĭn OI.
Zh Mikrobiol Epidemiol Immunobiol. 2011 Jan-Feb;(1):83-6. Study of efficacy of anaferon pediatric in mice infected by pandemic influenza virus A(H1N1/09)v. Shishkina LI, Skarnovich MO, Kabanov AS, Sergeev AA, Tarasov SA, Sergeeva SA, Épshteĭn, Malkova EM, Stavskiĭ EA, Drozdov IG.
Antiviral Research. Activity of ultra-low doses of antibodies to gamma-interferon against lethal influenza A (H1N1) 2009 virus infection in mice Sergey A. Tarasov, Vladimir V. Zarubaev, Evgeniy A. Gorbunov, Svetlana A. Sergeeva, Oleg I. Epstein. Journal of Medical Virology. Dose-Dependent Antiviral Activity of Released-Active Form of Antibodies to Interferon-Gamma against influenza A/California/07/09(H1N1) in Murine Model Еlena S. Don, Alexandra G. Emelyanova, Natalia N. Yakovleva, Nataliia V. Petrova, Marina V. Nikiforova, Evgeniy A. Gorbunov, Sergey А. Tarasov, Sergey G. Morozov,Оleg I. Epstein.